Pharming Group N.V. today announced 2026 financial guidance and will highlight its advancing clinical-stage rare disease pipeline, including two major value-creating programs, at a virtual Investor Day taking place later today.

Pharming Group N.V. today announced its preliminary, unaudited revenues for the full year 2025 and plans to host a virtual Investor Day on February 3, 2026, at 10:00 am EST (16:00 CET).

Pharming Group N.V. presents its preliminary (unaudited) financial report for the three months ended September 30, 2025.

Pharming Group N.V. confirms that it will report its preliminary (unaudited) financial results for the third quarter 2025 and provide a business update on Thursday, November 6, 2025.

Pharming Group N.V. presents its preliminary (unaudited) financial report for the second quarter and first half year ended June 30, 2025.

Pharming Group N.V. confirms that it will report its preliminary (unaudited) financial results for the second quarter and first half 2025 and provide a business update on Thursday, July 31, 2025.

Pharming Group N.V. presents its preliminary unaudited financial report for the three months ended March 31, 2025.

Pharming Group N.V. confirms it will report its preliminary (unaudited) first quarter 2025 financial results, for the period ended March 31, on Thursday, May 8, 2025.

Pharming Group N.V. announces the filing of its Annual Report for the year ended December 31, 2024 (the “Period”).

Pharming Group N.V. presents its preliminary (unaudited) financial report for the three months and full year ended December 31, 2024.